Assessing the values of circulating immune complexes in multiple sclerosis patients following immunomodulator or corticosteroid treatment

Docu Axelerad,Any; Stroe,Alina Zorina; Gogu,Anca Elena; Docu Axelerad,Daniel

doi:10.3892/etm.2021.9974

Assessing the values of circulating immune complexes in multiple sclerosis patients following immunomodulator or corticosteroid treatment

Authors:
- Any Docu Axelerad
- Alina Zorina Stroe
- Anca Elena Gogu
- Daniel Docu Axelerad
View Affiliations

Affiliations: Department of Neurology, Faculty of General Medicine, ‘Ovidius’ University of Constanta, 900470 Constanta, Romania, Department of Neurology, Faculty of General Medicine, Victor Babeș University of Medicine and Pharmacy Timișoara, 300041 Timisoara, Romania, Department of Sports, Faculty of Physical Education and Sports, ‘Ovidius’ University of Constanta, 900470 Constanta, Romania
Published online on: March 23, 2021 https://doi.org/10.3892/etm.2021.9974
Article Number: 542

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple sclerosis is defined as an immune‑mediated disease that affects the central nervous system, and also is characterized by the presence of immune cells and mediators which contribute to the subsidiary neuroinflammation associated with multiple sclerosis. Throughout the evolution of multiple sclerosis, it has been observed that circulating immune complexes (CICs) have higher values in these patients, especially in the acute phase of the disease. Thus, the aim of the present study was to observe, if in acute attack, relapsing‑remitting multiple sclerosis patients still present high values of CICs after treatment with glatiramer and prednisone. We divided 70 patients with multiple sclerosis with high values of CICs into two treatment groups, one treated with glatiramer (Copaxone) (immunomodulatory treatment) and the other with prednisone (corticosteroid treatment). After three months of treatment, we assessed the levels of CICs of the two multiple sclerosis groups and we observed that the patients that followed the immunomodulatory treatment had lower values of CICs than the group that followed the corticosteroid treatment. In addition, another observation established was that the glatiramer treatment group had higher levels of vitamin D in the serum than the prednisone group of multiple sclerosis patients. To conclude, better outcomes, from the point of view of the results obtained from the comparative analysis of the values of CICs and vitamin D, were demonstrated by following immunomodulatory treatment.

View Figures

View References

1	Dendrou CA, Fugger L and Friese MA: Immunopathology of multiple sclerosis. Nat Rev Immunol. 15:545–558. 2015.PubMed/NCBI View Article : Google Scholar
2	Howard J, Trevick S and Younger DS: Epidemiology of multiple sclerosis. Neurol Clin. 34:919–939. 2016.PubMed/NCBI View Article : Google Scholar
3	Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, et al: Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology. 83:278–286. 2014.PubMed/NCBI View Article : Google Scholar
4	Compston A and Coles A: Multiple sclerosis. Lancet. 372:1502–1517. 2008.PubMed/NCBI View Article : Google Scholar
5	Tabansky I, Messina MD, Bangeranye C, Goldstein J, Blitz-Shabbir KM, Machado S, Jeganathan V, Wright P, Najjar S, Cao Y, et al: Advancing drug delivery systems for the treatment of multiple sclerosis. Immunol Res. 63:58–69. 2015.PubMed/NCBI View Article : Google Scholar
6	Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A and Vollmer T: Brain health: Time matters in multiple sclerosis. Mult Scler Relat Disord. 9 (Suppl 1):S5–S48. 2016.PubMed/NCBI View Article : Google Scholar
7	Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P and Novelli F: T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon. Ann Neurol. 65:499–509. 2009.PubMed/NCBI View Article : Google Scholar
8	Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA and Cua DJ: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 201:233–240. 2005.PubMed/NCBI View Article : Google Scholar
9	Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B and Prat A: Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 13:1173–1175. 2007.PubMed/NCBI View Article : Google Scholar
10	Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM and Fugger L: Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 172:146–155. 2008.PubMed/NCBI View Article : Google Scholar
11	Rolla S, Bardina V, De Mercanti S, Quaglino P, De Palma R, Gned D, Brusa D, Durelli L, Novelli F and Clerico M: Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β. J Leukoc Biol. 96:1155–1164. 2014.PubMed/NCBI View Article : Google Scholar
12	Tachovsky TG, Lisak RP, Koprowski H, Theofilopoulos AN and Dixon FJ: Circulating immune complexes in multiple sclerosis and other neurological diseases. Lancet. 2:997–999. 1976.PubMed/NCBI View Article : Google Scholar
13	Jacques C, Davous P and Baumann N: Circulating immune complexes and multiple sclerosis. Lancet. 2(408)1977.PubMed/NCBI View Article : Google Scholar
14	Goust JM, Chenais F, Carnes JE, Hames CG, Fudenbergh HH and Hogan HL: Abnormal T cell subpopulations and circulating immune complexes in the Guillain-Barré syndrome and multiple sclerosis. Neurology. 28:421–425. 1978.PubMed/NCBI View Article : Google Scholar
15	Deicher H, Schwabedissen HM, Liman W, Baruth B, Patzold U and Haller P: Immune complexes in cerebrospinal fluid and serum of patients with multiple sclerosis. In: Progress in Multiple Sclerosis Research. Bauer HG, Poser S and Ritter G (eds). Verlag, Berlin, Springer, pp200-206, 1980.
16	Jans H, Jersild C, Taaning E, Dybkjaer E, Fog T and Heltberg A: The occurrence of immune complexes in patients with multiple sclerosis. In: Progress in Multiple Sclerosis Research. Bauer HG, Poser S and Ritter G (eds). Verlag, Berlin, Springer, pp195-199, 1980.
17	Schocket AL, Carr RI and Hardtke MA: A comparison of I125 Clq binding, Raji cell binding, and lymphocytotoxic activity in multiple sclerosis. Clin Immunol Immunopathol. 17:477–481. 1980.PubMed/NCBI View Article : Google Scholar
18	Trouillas P, Vincent C and Revillard JV: Clq binding circulating immune complexes in multiple sclerosis patients and their first-degree relatives: A distinctive immunological feature between sporadic and familial cases. J Clin Lab Immunol. 4:77–81. 1980.PubMed/NCBI
19	Noronha AB, Antel JP, Roos RP and Medof EM: Circulating immune complexes in neurologic disease. Neurology. 31:1402–1407. 1981.PubMed/NCBI View Article : Google Scholar
20	Tanaka Y, Tsukada N, Koh CS and Yanagisawa N: Anti-endothelial cell antibodies and circulating immune complexes in the sera of patients with multiple sclerosis. J Neuroimmunol. 17:49–59. 1987.PubMed/NCBI View Article : Google Scholar
21	Dasgupta MK, Warren KG, Johny KV and Dossetor JB: Circulating immune complexes in multiple sclerosis: Relation with disease activity. Neurology. 32:1000–1004. 1982.PubMed/NCBI View Article : Google Scholar
22	Tsukada N, Koh CS, Yanagisawa N and Tsukagoshi H: Nervous tissue injury induced by immune complexes. Acta Neuropathol. 56:279–284. 1982.PubMed/NCBI View Article : Google Scholar
23	Broman T: Blood-brain barrier damage in multiple sclerosis. Supravital test-observation. Acta Neurol Scand Suppl. 40 (Suppl 10):S21–S24. 1964.PubMed/NCBI View Article : Google Scholar
24	Aita JF, Benette DR, Anderson RE and Ziter F: Cranial CT appearance of acute multiple sclerosis. Neurology. 28:251–255. 1978.PubMed/NCBI View Article : Google Scholar
25	Lane B, Carrol BA and Pedley TA: Computerized cranial tomography in cerebral diseases of white matter. Neurology. 28:534–544. 1978.PubMed/NCBI View Article : Google Scholar
26	Ebers GC, Vinuela FV, Feasby T and Bass B: Multifocal CT enhancement in MS. Neurology. 34:341–346. 1984.PubMed/NCBI View Article : Google Scholar
27	Hershey LA, Gado MH and Trotter JL: Computerized tomography in the diagnostic evaluation of multiple sclerosis. Ann Neurol. 5:32–39. 1979.PubMed/NCBI View Article : Google Scholar
28	Dasgupta MK, Catz I, Warren KG, McPherson TA, Dossetor JB and Carnegie PR: Myelin basic protein: A component of circulating immune complexes in multiple sclerosis. Can J Neurol Sci. 10:239–243. 1983.PubMed/NCBI View Article : Google Scholar
29	Carson JH, Barbarese E, Braun PE and McPherson TA: Components in multiple sclerosis cerebrospinal fluid that are detected by radioimmunoassay for myelin basic protein. Proc Natl Acad Sci USA. 75:1976–1978. 1978.PubMed/NCBI View Article : Google Scholar
30	McPherson TA, Gilpin A and Seland TP: Radioimmunoassay of CSF for encephalitogenic basic protein: A diagnostic test for MS? Can Med Assn J. 107:856–859. 1972.PubMed/NCBI
31	Panitch HS, Hafler DA and Johnson KP: Antibodiestomyelin basic protein in cerebrospinal fluid of patients with multiple sclerosis. In: Progress in Multiple Sclerosis Research. Bauer HJ, Poser SR and Ritter G (eds). Springer-Verlag, Heidelberg, New York, pp98-105, 1980.
32	Tachovsky TG, Koprowski H, Lisak RP, Theofilopoulos AN and Dixon FJ: Circulating immune complexes in multiple sclerosis and other neurological diseases. Lancet. 308:997–999. 1976.PubMed/NCBI View Article : Google Scholar
33	Patzold U, Haller P, Baruth B, Liman W and Deicher H: Immune complexes in multiple sclerosis: Relation to clinical pattern. J Neurol. 222:249–260. 1980.PubMed/NCBI View Article : Google Scholar
34	Jans H, Heltberg A, Zeeberg I, Kristensen JH, Fog T and Raun NE: Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis. Acta Neurol Scand. 69:34–38. 1984.PubMed/NCBI View Article : Google Scholar
35	Wajgt A, Górny MK and Jenek R: The influence of high-dose prednisone medication on autoantibody specific activity and on circulating immune complex level in cerebrospinal fluid of multiple sclerosis patients. Acta Neurol Scand. 68:378–385. 1983.PubMed/NCBI View Article : Google Scholar
36	Munger KL, Levin LI, Hollis BW, Howard NS and Ascherio A: Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 296:2832–2838. 2006.PubMed/NCBI View Article : Google Scholar
37	Mowry EM, Krupp LB, Milazzo M, Chabas D, Strober JB, Belman AL, McDonald JC, Oksenberg JR, Bacchetti P and Waubant E: Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol. 67:618–624. 2010.PubMed/NCBI View Article : Google Scholar
38	Bhargava P, Steele SU, Waubant E, Revirajan NR, Marcus J, Dembele M, Cassard SD, Hollis BW, Crainiceanu C and Mowry EM: Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls. Mult Scler. 22:753–760. 2016.PubMed/NCBI View Article : Google Scholar